| gptkbp:instanceOf | gptkb:chemical_compound gptkb:drug
 
 | 
                        
                            
                                | gptkbp:approvalYear | 2012 
 | 
                        
                            
                                | gptkbp:approvedBy | gptkb:FDA gptkb:EMA
 
 | 
                        
                            
                                | gptkbp:ATCCode | N03AX22 
 | 
                        
                            
                                | gptkbp:brand | gptkb:Fycompa 
 | 
                        
                            
                                | gptkbp:CASNumber | 380917-97-5 
 | 
                        
                            
                                | gptkbp:contraindication | severe hepatic impairment 
 | 
                        
                            
                                | gptkbp:developer | gptkb:Eisai 
 | 
                        
                            
                                | gptkbp:eliminationHalfLife | 105 hours 
 | 
                        
                            
                                | gptkbp:excretion | urine feces
 
 | 
                        
                            
                                | gptkbp:hasMolecularFormula | C23H15N3O 
 | 
                        
                            
                                | gptkbp:hasSMILES | C1=CC=C(C=C1)C2=NN(C3=CC=CC=C32)C4=CC=CC=C4C=O 
 | 
                        
                            
                                | gptkbp:legalStatus | prescription only 
 | 
                        
                            
                                | gptkbp:mechanismOfAction | gptkb:AMPA_receptor_antagonist 
 | 
                        
                            
                                | gptkbp:metabolism | liver (CYP3A4, CYP3A5) 
 | 
                        
                            
                                | gptkbp:molecularWeight | 349.39 g/mol 
 | 
                        
                            
                                | gptkbp:pregnancyCategory | gptkb:B3 C
 
 | 
                        
                            
                                | gptkbp:proteinBinding | 95% 
 | 
                        
                            
                                | gptkbp:PubChem_CID | gptkb:CHEMBL2105757 8067855
 9887873
 
 | 
                        
                            
                                | gptkbp:routeOfAdministration | oral 
 | 
                        
                            
                                | gptkbp:sideEffect | dizziness falls
 aggression
 irritability
 somnolence
 
 | 
                        
                            
                                | gptkbp:synonym | E2007 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile
 
 | 
                        
                            
                                | gptkbp:UNII | 4Y49E3L79L 
 | 
                        
                            
                                | gptkbp:usedFor | epilepsy partial-onset seizures
 primary generalized tonic-clonic seizures
 
 | 
                        
                            
                                | gptkbp:bfsParent | gptkb:Fycompa 
 | 
                        
                            
                                | gptkbp:bfsLayer | 7 
 | 
                        
                            
                                | https://www.w3.org/2000/01/rdf-schema#label | perampanel 
 |